Overview

A Trial to Learn if a COVID-19 Therapeutic is Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants

Status:
Not yet recruiting
Trial end date:
2023-08-23
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the safety and tolerability of REGN14284 in healthy participants, as measured by all treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (SAEs). The secondary objectives of the study are: - To assess the concentration-time profile of REGN14284 in serum - To assess the immunogenicity of REGN14284
Phase:
Phase 1
Details
Lead Sponsor:
Regeneron Pharmaceuticals